20 completed, 6 recruiting, 4 terminated, 3 unknown. 20 Phase 1, 6 Not applicable, 4 Phase 2, 3 Early Phase 1, 2 Phase 4.
Follow Refractory Solid Tumors: new trials by email Literature Review of Refractory Solid Tumors trials Research Report on Refractory Solid Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors PEEL-224, Vincristine, Temozolomide (TMZ) - Refractory Solid Tumors, Relapsed Solid Tumors | Phase 1 / Phase 2 | Recruiting | Theodore Laetsch | 59 | 2025-03-23 | 2026-10-06 |
| Personalized KSX01-TCRT in Patients With Advanced Solid Tumors KSX01-TCRT cell therapy - Refractory Solid Tumors, Relapsed Solid Tumors | Early Phase 1 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 12 | 2023-11-07 | 2025-03-26 |
| A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors Eribulin, Irinotecan, Temozolomide - Refractory Solid Tumors | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 48 | 2023-08-16 | 2026-05-20 |
| KSX01-TCRT Injection Project in Solid Tumors KSX01-TCRT injection - TCR-T Cells, Refractory Solid Tumors | Early Phase 1 | Recruiting | TCRx Therapeutics Co.Ltd | 50 | 2023-03-07 | 2026-10-26 |
| KSH01-TCRT Solid Tumors KSH01 injection - TCR-T Cells, Refractory Solid Tumors | Early Phase 1 | Recruiting | TCRx Therapeutics Co.Ltd | 50 | 2022-08-19 | 2026-10-23 |
| Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid Tumors BNA035 - Refractory Solid Tumors | Phase 1 | Unknown | Binacea Pharma, Inc. | 48 | 2022-02-08 | 2022-09-27 |
| Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation Arsenic trioxide - Refractory Solid Tumors | Phase 2 | Unknown | Ruijin Hospital | 20 | 2021-04-20 | 2021-05-13 |
| A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC) KB-0742 - Relapsed Solid Tumors, Refractory Solid Tumors | Phase 1 / Phase 2 | Terminated | Kronos Bio | 135 | 2021-02-08 | 2025-02-17 |
| MyCustom:Prospective Master Protocol Trial on Precision Medicine Treatment for Refractory Solid Tumors Refractory Solid Tumors, Next Generation Sequencing | Unknown | Tianjin Medical University Second Hospital | 400 | 2020-12-01 | 2023-09-11 | |
| Nanoliposomal Irinotecan (Nal-IRI, ONIVYDE®) in Combination With TAS-102 (LONSURF®) in Refractory Solid Tumors Nanoliposomal Irinotecan - Refractory Solid Tumors | Phase 1 | Completed | PharmaEngine | 44 | 2019-03-05 | 2023-11-18 |
| Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors Malignant Solid Tumors, Other Neoplasms Solid Tumors | Recruiting | National Cancer Institute (NCI) | 10000 | 2019-01-28 | 2026-10-29 | |
| TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101) IMA201 Product, IMADetect® - Solid Tumor, Cancer | Phase 1 | Completed | Immatics US, Inc. | 7 | 2018-12-19 | 2025-02-04 |
| Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors Sunitinib - Refractory Solid Tumors | Phase 4 | Completed | Samsung Medical Center | 1 | 2017-11-20 | 2022-06-15 |
| A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors IMO-2125 - Refractory Solid Tumors, Melanoma | Phase 1 | Completed | Idera Pharmaceuticals, Inc. | 54 | 2017-06-09 | 2020-02-11 |
| Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer IT-141 - Cancer, Neoplasms | Phase 1 | Terminated | Intezyne Technologies, Inc. | 10 | 2017-03-23 | 2020-12-22 |
| Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors sirolimus - Refractory Solid Tumors | Phase 4 | Completed | Samsung Medical Center | 6 | 2017-02-05 | 2022-06-15 |
| Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors Sorafenib - Refractory Solid Tumors | Not applicable | Withdrawn | Samsung Medical Center | 2016-12-23 | 2019-12-30 | |
| Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors sorafenib - Refractory Solid Tumors | Not applicable | Completed | Samsung Medical Center | 1 | 2016-05-30 | 2017-03-13 |
| Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors pazopanib - Refractory Solid Tumors | Not applicable | Completed | Samsung Medical Center | 2 | 2016-05-01 | 2022-06-15 |
| Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors sunitinib - Refractory Solid Tumors | Not applicable | Completed | Samsung Medical Center | 1 | 2016-03-23 | 2022-06-15 |
Showing 20 of 35. Sign in to see all of them.
Neoplasms (5) · Lymphoma (3) · Recurrence (3) · Leukemia (2) · Colorectal Neoplasms (1) · Lymphoma, Non-Hodgkin (1) · Melanoma (1) · Neoplasm Metastasis (1) · Neuroblastoma (1) · Pancreatic Neoplasms (1) · Rhabdomyosarcoma (1)
Neoplasms (10) · Neoplasms by Histologic Type (8) · Hemic and Lymphatic Diseases (6) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoproliferative Disorders (4) · Disease Attributes (3) · Neoplasms by Site (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Hematologic Diseases (2) · Neoplasms, Germ Cell and Embryonal (2)
Sorafenib (4) · Irinotecan (3) · Cyclophosphamide (2) · Sunitinib (2) · Temozolomide (2) · eribulin (2) · pazopanib (2) · ASP4132 (1) · AVN 944 (1) · AZD2461 (1) · Arsenic Trioxide (1) · Azurin (1) · Bevacizumab (1) · Cefixime (1) · Dasatinib (1)
Samsung Medical Center (7) · TCRx Therapeutics Co.Ltd (2) · Astellas Pharma Global Development, Inc. (1) · AstraZeneca (1) · Binacea Pharma, Inc. (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Dr. Tapas K. Das Gupta (1) · Duke University (1) · Eisai Inc. (1) · Erimos Pharmaceuticals (1) · Idera Pharmaceuticals, Inc. (1) · Immatics US, Inc. (1) · Intezyne Technologies, Inc. (1) · Kronos Bio (1) · M.D. Anderson Cancer Center (1)
United States (20) · South Korea (7) · China (5) · Australia (1) · Canada (1) · Germany (1) · Israel (1) · Mexico (1) · Spain (1) · Taiwan (1) · United Kingdom (1)
Jie Ma (2) · Alfonso Duenas-Gonzalez, MD PhD (1) · Andrew Hughes, MA, MB, ChB, PhD, P (1) · Carrye Cost, MD (1) · Cedrik Britten, MD, PhD (1) · Chia-Chi Lin, MD (1) · David R. Spigel, M.D. (1) · Dr. Jeffrey Infante, MD (1) · Fiorela Hernandez Tejada, MD (1) · Haitao Wang, Ph.D (1) · Hope C Uronis, MD (1) · Jacquelyn Crane, MD (1) · Josh Xiao, PhD (1) · Jun Zhang, MD & PhD (1)
PMID 17761710, PMID 26999488, PMID 29505699, PMID 33830407, PMID 35417717
2023 (1)